Provided By PR Newswire
Last update: Oct 30, 2024
NEW YORK, Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Read more at prnewswire.comNASDAQ:BCLI (2/21/2025, 8:02:56 PM)
1.73
-0.07 (-3.89%)
Find more stocks in the Stock Screener